Associated Banc Corp cut its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 4.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 42,803 shares of the financial services provider’s stock after selling 2,173 shares during the period. Associated Banc Corp’s holdings in iShares Biotechnology ETF were worth $5,659,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. boosted its stake in shares of iShares Biotechnology ETF by 1.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after acquiring an additional 82 shares during the last quarter. Transcend Capital Advisors LLC lifted its position in iShares Biotechnology ETF by 0.8% during the fourth quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after buying an additional 92 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in iShares Biotechnology ETF by 2.5% during the fourth quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock worth $510,000 after buying an additional 94 shares in the last quarter. WealthCare Investment Partners LLC lifted its position in iShares Biotechnology ETF by 0.9% during the fourth quarter. WealthCare Investment Partners LLC now owns 10,348 shares of the financial services provider’s stock worth $1,375,000 after buying an additional 96 shares in the last quarter. Finally, Capital Investment Advisors LLC lifted its position in iShares Biotechnology ETF by 1.0% during the fourth quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock worth $1,381,000 after buying an additional 99 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Performance
Shares of iShares Biotechnology ETF stock opened at $134.19 on Friday. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57. The company has a market cap of $6.34 billion, a price-to-earnings ratio of 24.52 and a beta of 0.84. The business’s 50 day moving average price is $136.25 and its 200 day moving average price is $139.96.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- Golden Cross Stocks: Pattern, Examples and Charts
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Insider Trades May Not Tell You What You Think
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- How to Invest in Insurance Companies: A Guide
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.